David Hovland
General Counsel bei ELEDON PHARMACEUTICALS, INC.
Profil
David Hovland is currently the Chief Regulatory Officer at Eledon Pharmaceuticals, Inc. Prior to this, he was the Senior Vice President-Global Regulatory Affairs at Urovant Sciences Ltd.
from 2018 to 2021.
He was also the Vice President-Global Regulatory Affairs at Allergan Ltd.
(Ireland) from 2015 to 2018.
Before that, he was the Director-Global Regulatory Affairs at Amgen, Inc. from 2006 to 2010.
He started his career as a Study Director at Allergan Ltd.
(Ireland) from 1999 to 2002.
Dr. Hovland holds a doctorate degree from the University of California, Los Angeles and an undergraduate degree from the University of California, Berkeley.
Aktive Positionen von David Hovland
| Unternehmen | Position | Beginn |
|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | General Counsel | 19.04.2021 |
Ehemalige bekannte Positionen von David Hovland
| Unternehmen | Position | Ende |
|---|---|---|
| UROVANT SCIENCES LTD. | General Counsel | 01.04.2021 |
| ALLERGAN PLC | General Counsel | 01.01.2018 |
| AMGEN INC. | General Counsel | 01.01.2010 |
| ALLERGAN PLC | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von David Hovland
| University of California, Los Angeles | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
